Mayo Clinic Ventures and NTT Venture Capital have invested in the AI software developer to synthesize biomedical data for drug development and precision medicine.
The new system, called BODE 2, will launch at the end of this year and will replace the existing BODE for the analysis of "big omics" data for research.
Analyzing patient exome sequence data, investigators identified germline variants with apparent ties to estrogen receptor-positive breast cancer recurrence.
The "augmented intelligence" startup applies machine learning and contextual language processing to make sense of multi-omics datasets and inform drug discovery.
Hatched from the computational genomics lab at Ghent University, BioLizard offers a small but complementary team to tackle AI and molecular pipeline challenges.
The anonymous gift, to be made in annual installments over 10 years, will support interdisciplinary work at the campus's Genomics Institute headquarters.
The Wellcome Trust has granted the University of Dundee five more years of support to help bioinformaticians develop a web-compatible JavaScript version of the software.
Bioinformaticians at the Free University of Brussels have built a database, machine learning technology, and web platform for identifying elusive pathogenic gene pairs.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
